ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Sandwich therapy combining photodynamic therapy and adjunctive anti-VEGF for juxtapapillary retinal capillary hemangioblastoma.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Somatic Driver to Molecular Therapy in Retinal, Choroidal and Periocular Vascular Disease: Mosaicism, Targetable Pathways and Ocular Toxicity.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report the outcomes of verteporfin photodynamic therapy (PDT) with adjuntive pre- and post-PDT intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections ("Sandwich PDT") for juxtapapillary retinal capillary hemangioblastoma (RCH).
methodsA retrospective case review of eyes with juxtapapillary RCH that underwent "Sandwich PDT" in a national referral center. The clinical features were evaluated with fundus photography, optical coherence tomography, and ultrasonography.
resultsFive eyes were analyzed. The median follow-up time was 42 (range, 12-77) months. Adjunctive anti-VEGFs were given 4.0 weeks (range, 1 day-12 weeks) before PDT and 6.0 weeks (3 days to 8 weeks) after PDT. One of the five eyes (20%) that had anti-VEGF injection 8 weeks before PDT developed macular exudation after PDT but resolved within 1 month. Following Sandwich PDT, tumor size regressed in 3/5 eyes (60%) and stabilized in 2/5 eyes (40%). Subretinal fluid and exudates completely resolved in the three eyes that had these features before PDT, whereas intraretinal fluid stabilized or partially responded in 4/5 (80%). Reactivation of disease activity was noted in two eyes (40%), one resolved after a second Sandwich PDT. At the last follow-up, visual acuity improved 10 ETDRS letters or more in one eye (20%), stabilized in two (40%), and worsened 10 ETDRS letters or more in two (40%).
conclusionThe treatment of juxtapapillary RCH remains challenging. PDT with adjunctive anti-VEGF injections achieved anatomical control, but the functional outcomes were guarded. Based on the pharmacokinetics, we propose that anti-VEGF be given 1 week before PDT for maximal coverage.
Indexed as
Identifiers
42371029What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.